Genentech, Inc.

This study gives ongoing access to the cancer drug trastuzumab emtansine (given alone or with other therapies) for people with metastatic cancer who were already benefiting from it in a previous trial. The main goal is to monitor safety, including side effects. About 720 particip…

This study follows about 400 adults and children with spinal muscular atrophy (SMA) who are taking risdiplam (Evrysdi) to see how safe and effective it is over the long term. Participants will be monitored for about 2 years, and the study tracks side effects and changes in their …

This study looks at whether adding the drug venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) reach very deep remission. The goal is to allow patients to stop all treatment for a period of time. About 118 adults who have been on …

This study tests a new drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The goal is to see if it can shrink tumors and keep the cancer from growing for as long as possible. About 320 participants will take part to c…

This early-phase study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific gene change (NRAS mutation) and has stopped responding to standard immunotherapy. The main goals are to check s…

This study tests the drug faricimab in people with diabetic macular edema (swelling in the back of the eye due to diabetes) who have not been treated before. It focuses on Black, Hispanic, Native American, and Asian Indian participants, groups often underrepresented in research. …

This early-stage study tests a new medicine called RO7497372 for people with diabetic macular edema, a condition that causes vision loss. The study involves 151 participants and checks if the drug is safe and how it works in the body. The medicine is given as an injection into th…

This study tests a new drug called GDC-9545, alone or with other medicines, in people with advanced or spreading ER-positive/HER2-negative breast cancer. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 181 participants will take p…

This early-stage trial tests a new drug called cevostamab, alone or with other medicines, in people whose multiple myeloma has returned or stopped responding to treatment. The main goals are to find the safest dose and check for side effects. About 126 participants will receive t…

This early-stage study tests two drugs, XmAb24306 and cevostamab, together in people with multiple myeloma that has come back or not responded to at least three prior treatments. The main goal is to see if the combination is safe and to find the best dose. About 90 participants w…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, pancreatic, or bladder cancers. The main goal is to check safety and how well the body handles the drug. Abo…

This early-stage trial tests a new drug called runimotamab, given alone or with trastuzumab, in people with advanced HER2-expressing cancers. The main goal is to check safety and how the drug moves through the body. About 123 adults with solid tumors that have spread or cannot be…

This early-stage study tests an experimental treatment called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to check if it is safe and how the body handles it. Researchers will also measure how long the treatment lasts in the blood and how it affects imm…

This study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colon cancer) that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and how well it works, both alone and with other cancer treatments. About 500 participan…